Key Summary
- Health officials are urging to investigate deaths due to weight loss injections in the black market.
- The parliamentary cross-examination focused heavily on how strict NHS access constraints are inadvertently creating severe patient safety risks.
- Minister Hodgson stressed that the government must go "further and faster" to expand legitimate obesity drug rollouts.
Health officials are facing urgent calls to investigate patient deaths linked to black market weight-loss injections.
During a Health and Social Care Committee session, MPs directly challenged NHS and Department of Health leaders over measures to curb the illicit sales of anti-obesity treatments.
Committee members pointed out that people have already died as a result of accessing these unregulated products, and the situation will get worse if immediate action is not taken.
The parliamentary cross-examination focused heavily on how strict NHS access constraints are inadvertently creating severe patient safety risks.
As per the NHS norms, people having a body mass index (BMI) of 40 or more and have been diagnosed with four of the weight-related health problems (dyslipidaemia or abnormal fat levels in the blood, hypertension, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes) are eligible for weight loss jabs.
Conservative MP Gregory Stafford cited evidence that current barriers are pushing desperate patients toward potentially lethal, unregulated sources.
Public health minister Sharon Hodgson conceded that restricted access was driving people towards the black market, advising the public to stick to registered community or online pharmacies, while acknowledging that the wider issue of limited supply ultimately traces back to intense NHS cost pressures.
A harrowing account from committee chairwoman Layla Moran underscored the immediate human cost of the regulatory failure.
Moran shared that she has met with families of victims who tragically contracted sepsis and died after administering black market jabs.
She noted that ongoing coroner reports suggest the injection itself and its improper administration caused the fatalities, adding that grieving families left the hearing feeling that neither the MHRA (Medicines and Healthcare products Regulatory Agency) nor NHS leadership are truly on top of the crisis.
In response to the mounting pressure, Minister Hodgson stressed that the government must go "further and faster" to expand legitimate obesity drug rollouts, admitting that current treatment numbers are insufficient.
She affirmed that the NHS needs to scale up access "at pace" and suggested a new single patient record system could help streamline the identification of eligible patients.
Highlighting the broader cultural barriers to obesity care, Hodgson also shared a personal anecdote about a GP who once called her "fat" as a "shock tactic" during a routine blood pressure check, emphasizing the deep-rooted medical stigma that leaves patients feeling crestfallen and alienated from safe healthcare channels.
Dr Kieran Seyan, chief medical officer at LloydsPharmacy Online Doctor said, “Rising demand for weight loss medication, alongside restricted access through NHS pathways appears to be contributing to some patients seeking these treatments from unregulated sources.
“Our research shows that more than a quarter of people using weight loss drugs (28 percent) have bought injections from unlicensed sellers, while one in five are using treatments that haven’t been licensed for use in the UK. There is also emerging concern that the newer oral formulations of the GLP-1 medications may be more vulnerable to counterfeiting.
“Current NHS eligibility criteria (typically a BMI of 35 with at least one weight related comorbidity), are an understandable starting point, but may help explain why a significant proportion of patients of the patients are accessing treatment privately.
“Improving access within regulated services may help support wider and safer use of the treatments when delivered as part of a weight management pathway, incorporating clinical oversight, ongoing monitoring and wrap around care.
“It is important that patients access weight loss medications only through appropriately regulated healthcare professionals. Obtaining medication from unregulated sources carries risk, including incorrect dosing, expired or improperly stored medication, or counterfeit products.”
